Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry P Erba

Showing results (11-20 of 123) with videos related to

Pageof 13
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|October 1, 2013
Expert insights into the contemporary management of older adults with acute myeloid leukemiaFarhad Ravandi, Harry P Erba, Daniel A Pollyea
Expert Review of Anticancer Therapy|November 27, 2012
Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLUma Borate, Devin Absher, Harry P Erba, et al.
Lancet (London, England)|April 17, 2023
Acute myeloid leukaemiaCourtney D DiNardo, Harry P Erba, Sylvie D Freeman, et al.
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinibHarry P Erba, Dat C Pham, Robert Zaiden, et al.
Leukemia Research|October 10, 2018
Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrowOmer Jamy, Sejong Bae, Luciano J Costa, et al.
Haematologica|December 21, 2014
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemiaBruno C Medeiros, Megan Othus, Min Fang, et al.
Hematology/Oncology and Stem Cell Therapy|October 21, 2019
Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case SeriesGaurav Shah, Fady M Mikhail, Kimo Bachiasvili, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|April 28, 2007
In vitro and in silico analysis of annexin V binding to lymphocytes as a biomarker in emergency department sepsis studiesColin F Greineder, Patrick W Nelson, Amanda L Dressel, et al.
Pharmacotherapy|June 28, 2007
Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropeniaNadine Shehab, Daryl D DePestel, Emily R Mackler, et al.
Leukemia & Lymphoma|February 9, 2021
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203Anna Moseley, Megan Othus, Guillermo Garcia-Manero, et al.
Pageof 13

Showing results (11-20 of 123) with videos related to

Sort By:
Pageof 13
Cancer Control : Journal of the Moffitt Cancer Center|October 1, 2013
Expert insights into the contemporary management of older adults with acute myeloid leukemiaFarhad Ravandi, Harry P Erba, Daniel A Pollyea
Expert Review of Anticancer Therapy|November 27, 2012
Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLUma Borate, Devin Absher, Harry P Erba, et al.
Lancet (London, England)|April 17, 2023
Acute myeloid leukaemiaCourtney D DiNardo, Harry P Erba, Sylvie D Freeman, et al.
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinibHarry P Erba, Dat C Pham, Robert Zaiden, et al.
Leukemia Research|October 10, 2018
Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrowOmer Jamy, Sejong Bae, Luciano J Costa, et al.
Haematologica|December 21, 2014
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemiaBruno C Medeiros, Megan Othus, Min Fang, et al.
Hematology/Oncology and Stem Cell Therapy|October 21, 2019
Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case SeriesGaurav Shah, Fady M Mikhail, Kimo Bachiasvili, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|April 28, 2007
In vitro and in silico analysis of annexin V binding to lymphocytes as a biomarker in emergency department sepsis studiesColin F Greineder, Patrick W Nelson, Amanda L Dressel, et al.
Pharmacotherapy|June 28, 2007
Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropeniaNadine Shehab, Daryl D DePestel, Emily R Mackler, et al.
Leukemia & Lymphoma|February 9, 2021
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203Anna Moseley, Megan Othus, Guillermo Garcia-Manero, et al.
Pageof 13